TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27430621
Drug: Coaching plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coaching plus light therapy and pulsed electromagnetic field therapy for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Study: 27430621
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with light and pulsed electromagnetic field switched to placebo settings for 12 weeks, twice a week for 40 min, and coaching once a fortnight for 50 min
Study: 21755540
Drug: Asenapine 2
Normalized name: asenapine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 2 mg BID for 2 days, then 5 mg BID for 2 days, then 10 mg BID thereafter (slow escalation)
Study: 21755540
Drug: Asenapine 5
Normalized name: asenapine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asenapine 5 mg BID for 4 days, then 10 mg BID thereafter (rapid escalation)
Study: 19634922
Drug: Fibrin-specific lytic
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin-specific lytic (FSL) plus unfractionated heparin (UFH)
Study: 14996675
Drug: Higher tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tidal volume ventilation (12 mL/kg of predicted weight)
Study: 14996675
Drug: Lower tidal
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower tidal volume ventilation (6 mL/kg of predicted weight)
Study: 11724641
Drug: Intravenous glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous glutamate infusion (125 mmol x l(‐1) at a rate of 1.5 ml x h(‐1) x kg(‐1) for 1 hour)
Study: 11724641
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (0.9% NaCl)
Study: 3248354
Drug: Oxandrolone 2.5
Normalized name: oxandrolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 2.5 mg/day for 3 months
Study: 29695895
Drug: CBZ+BMT (Carbamazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBZ+BMT (Carbamazepine 200 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Study: 29695895
Drug: OXC+BMT (Oxcarbazepine
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXC+BMT (Oxcarbazepine 300 mg, Betahistine Mesilate 12 mg or 18 mg, twice daily)
Study: 29695895
Drug: BMT 18
Normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT 18 mg
Study: 29695895
Drug: BMT 12
Normalized name: BMT IM
DrugBank: Biomodulin T (DB16529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMT 12 mg
Study: 21710615
Drug: Antiresorptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive treatment (alendronate, clodronate, denosumab, lasofoxifene, zoledronic acid)
Study: 21710615
Drug: Antiresorptive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiresorptive treatment
Study: 16915526
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion (ISI)
Study: 16915526
Drug: Sodium lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate infusion (SLI)
Study: 3607806
Drug: Frusemide (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (0.5 mg/kg intravenously)
Study: 3607806
Drug: Isosorbide 5‐mononitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide 5‐mononitrate (15 mg intravenously)
Study: 26260043
Drug: Dietitian referral
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietitian referral for medical nutrition therapy (RD)
Study: 21467128
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg/day
Study: 21965488
Drug: Cyclobenzaprine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclobenzaprine (10 mg once per day before surgery, day of surgery, and first day after surgery)
Study: 15225171
Drug: ibuprofen 800
Normalized name: ibuprofen 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 800 mg three-times daily
Study: 9198491
Drug: 40 ml
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 ml Gd-DTPA with three successive acquisitions at fixed intervals (25, 53 and 81 s)
Study: 9198491
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml Gd-DTPA with individually determined MR acquisition start based on prior evaluation of contrast material transit times
Study: 28939185
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (glue and antibiotic ointment)
Study: 26438179
Drug: Propofol +
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol + remifentanil (5 ng.mL(‐1))
Study: 19739696
Drug: Iloperidone (6-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iloperidone (6-12 mg twice daily)
Study: 12040346
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 or 60 mg given every 12 hours for 14 days)
Study: 12040346
Drug: Ticlopidine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidine (250 mg twice daily for 14 days)
Study: 9672165
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with alpha-interferon and lamivudine for 16 weeks
Study: 7729237
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 500 mg/day, administered seven to nine hours after awakening (R x 2)
Study: 7729237
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 500 mg/day, administered within two hours of awakening (R x 1)
Study: 7729237
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) 500 mg/day, administered within two hours before bedtime (R x 3)
Study: 2686410
Drug: Ciprofloxacin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (200 mg every 12 hours intravenously, then oral)
Study: 2686410
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 to 2 g intravenously every eight to 12 hours)
Study: 31120118
Drug: Rivaroxaban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (oral factor Xa inhibitor) given at the approved dose for PE for ≥3 months
Study: 31120118
Drug: Rivaroxaban (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (oral factor Xa inhibitor)
Study: 25688780
Drug: Varenicline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Varenicline (1 mg twice daily for 24 weeks)
Study: 16287132
Drug: BNS (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNS (nutrition support delivered before treatment)
Study: 16287132
Drug: TNS (nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNS (nutrition support delivered during treatment)
Study: 11162750
Drug: adjunctive remacemide
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjunctive remacemide hydrochloride 150 mg q.i.d. for 4 weeks
Study: 11162750
Drug: adjunctive remacemide
Normalized name: Remacemide
DrugBank: Remacemide (DB06458)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjunctive remacemide hydrochloride
Study: 9057729
Drug: IVIg (0.15-0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (0.15-0.2 g/kg bodyweight, monthly for 2 years)
Study: 8392903
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin starting from 45 mg/m2 every 3 weeks for six courses (Group A)
Study: 8392903
Drug: Cisplatin 60
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 60 mg/m2, etoposide 120 mg/m2 x 3, and escalating epirubicin with GM-CSF priming from day -17 to -7 (Group C)
Study: 4004191
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (250 mg + 125 mg) three times daily for 7 days
Study: 4004191
Drug: Cephalexin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (250 mg) three times daily for 7 days
Study: 4004191
Drug: Amoxicillin-clavulanic acid
Normalized name: amoxicillin / clavulanate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin-clavulanic acid (for ampicillin-resistant strains)
Study: 30807663
Drug: GSK561679 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK561679 350 mg/day for 6 weeks
Study: 30029620
Drug: Dihydroartemisinin-piperaquine administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine administered in the community without an SMS reminder
Study: 30029620
Drug: Dihydroartemisinin-piperaquine administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine administered in the community with an SMS reminder
Study: 30029620
Drug: Dihydroartemisinin-piperaquine administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine administered in the community with a community health worker reminder
Study: 30029620
Drug: Dihydroartemisinin-piperaquine administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine administered at the hospital with an SMS reminder
Study: 30029620
Drug: Dihydroartemisinin-piperaquine administered
Normalized name: .alpha.-dihydroartemisinin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroartemisinin-piperaquine administered at the hospital without an SMS reminder
Study: 16198885
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (LAVI > 34 mL/m2)
Study: 11477904
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of tetramethylpyrazine (TMP) dripped intravenously after anesthesia and 1 mg/kg of TMP infused into oxygenator after CPB
Study: 12764908
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TMP treatment)
Study: 7657041
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every other day
Study: 7657041
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg on weekends
Study: 2784977
Drug: Propofol continuous
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol continuous infusion for 3 days
Study: 20121889
Drug: Fish-oil supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil supplement (4 g/day, n = 49)
Study: 17956874
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (fibrinolysis)
Study: 12804125
Drug: Methylphenidate (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (various doses)
Study: 6333182
Drug: Epidermal growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidermal growth factor, applied topically four times a day on the day of surgery and twice a day for two days thereafter.
Study: 22469850
Drug: Chondroitin sulfate
Normalized name: Chondroitin Sulfate
DrugBank: Chondroitin sulfate (DB09301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chondroitin sulfate and glucosamine hydrochloride (combination therapy)
Study: 18595980
Drug: Synbiotics (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (4 probiotic species: Lactobacillus rhamnosus GG and LC705, Bifidobacterium breve Bb99, and Propionibacterium freudenreichii ssp shermanii) with 0.8 g of galactooligosaccharides, daily for 6 months after birth.
Study: 18595980
Drug: Placebo, daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, daily for 6 months after birth.
Study: 16149682
Drug: Combined antibiotic
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)
Study: 10396665
Drug: Albunex 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex 0.10 ml/kg
Study: 10396665
Drug: Albunex 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex 0.15 ml/kg
Study: 10396665
Drug: Albunex 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex 0.20 ml/kg
Study: 10396665
Drug: Albunex (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albunex (all doses)
Study: 2123909
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone (2 mg/kg body weight per 10 min)
Study: 2123909
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg per 10 min)
Study: 22841452
Drug: Xylazine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylazine (loading dose: 1mg/kg, CRI: 0.69mg/kg/h for 2h)
Study: 22841452
Drug: Romifidine (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Romifidine (loading dose: 80μg/kg, CRI: 30μg/kg/h for 2h)
Study: 21199965
Drug: Donepezil and
Normalized name: donepezil and memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil and antidepressant therapy
Study: 19880458
Drug: Citalopram (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (initial treatment)
Study: 19880458
Drug: Subsequent randomized
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subsequent randomized trials (switching or augmenting treatments)
Study: 19880458
Drug: Two vigorous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two vigorous medication trials
Study: 19880458
Drug: Complicated medication
Normalized name: AVOBENZONE 3 g in 100 g / HOMOSALATE 10 g in 100 g / OCTISALATE 5 g in 100 g / OCTOCRYLENE 10 g in 100 g / OXYBENZONE 5 g in 100 g TOPICAL AEROSOL, SPRAY [UNCOMPLIKATED MAKEUP SETTING SPF 50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated medication regimens
Study: 9516030
Drug: Acetaminophen 0.5
Normalized name: ACETAMINOPHEN 0.5 g in 1 g ORAL TABLET [Acetaminophen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 0.5 g
Study: 2971603
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg by mouth)
Study: 2971603
Drug: Spectinomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spectinomycin (2 g intramuscularly)
Study: 24384584
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 0.0125 μg(−1) kg(−1) min
Study: 26277524
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HBO therapy)
Study: 20598107
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV iron sucrose (Venofer(®), 200 mg)
Study: 20598107
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron sulphate (Duroferon(®), 20×100 mg)
Study: 16286670
Drug: Chronic L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic L-carnitine L-tartrate supplementation
Study: 16286670
Drug: Acute L-carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute L-carnitine L-tartrate supplementation
Study: 11203580
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of polylactide membrane plus polyglactin root‐lining mesh (Vicryl) and demineralized freeze‐dried bone allograft (DFDBA) (GVB sites)
Study: 9302150
Drug: Fleroxacin 200
Normalized name: fleroxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin 200 mg once daily
Study: 8365829
Drug: Albuterol (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol (360 micrograms total dose, 90 micrograms per dose, 4 doses)
Study: 3046300
Drug: Glucose loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose loading (100 g glucose) in non-pregnant women
Study: 3046300
Drug: Glucose loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose loading (100 g glucose) in early-pregnant women
Study: 3046300
Drug: Glucose loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose loading (100 g glucose) in late-pregnant women
Study: 21566549
Drug: CST+OS (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST+OS (conventional standard therapy combined with oral supplementation) for 4 months
Study: 21566549
Drug: CST (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: CST (conventional standard therapy alone)
Study: 19943706
Drug: Sorafenib, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib, a multi‐tyrosine kinase inhibitor, approved as first‐line therapy in HCC.
Study: 15636308
Drug: S‐Amlodipine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐Amlodipine 2.5 mg
Study: 11376633
Drug: Cerivastatin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin (0.4 mg once daily)
Study: 2892544
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of famotidine
Study: 2892544
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of famotidine
Study: 30777900
Drug: Intravenous dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous dexamethasone 8 mg/2 mL
Study: 30777900
Drug: Control (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (2 mL of saline)
Study: 24093810
Drug: Stages of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stages of change (contemplation and preparation)
Study: 18294484
Drug: Simvastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (n = 124; 160 mg total, 40 mg orally every 12 hours starting the evening before and ending the morning after the procedure)
Study: 11190646
Drug: Open dorsoventral
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open dorsoventral interval therapy using the TAC
Study: 9083323
Drug: Norgestimate-ethinyl estradiol
Normalized name: norgestimate-ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norgestimate-ethinyl estradiol (active OC treatment)
Study: 8471696
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg brofaromine twice a day
Study: 8471696
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg phenelzine three times a day
Study: 3534966
Drug: Postoperative total
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative total pelvic irradiation plus misonidazole (MISO) (1 g/m2 orally 2 h before the first daily fraction)
Study: 3534966
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (cystectomy alone)
Study: 16335887
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release nifedipine (20 mg/day) plus candesartan (8 mg/day)
Study: 16335887
Drug: Candesartan (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (12 mg/day) - up-titrated monotherapy
Study: 16335887
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release nifedipine plus candesartan combination therapy
Study: 16335887
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with controlled release nifedipine and low-dose candesartan
Study: 11910308
Drug: Losartan titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan titration to 100 mg
Study: 11910308
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg addition
Study: 4723266
Drug: Quinine dihydrochloride
Normalized name: quinine dihydrochloride
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quinine dihydrochloride (490 mg base) via intravenous infusion every 8 hours for 3 days (1.47 gm base daily)
Study: 4723266
Drug: Enteric‐coated tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric‐coated tablets of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Study: 4723266
Drug: Gelatin capsules
Normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsules of quinine sulfate (540 mg base) given orally every 8 hours for 3 days (1.62 gm base daily)
Study: 23037875
Drug: Late administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Late administration of surfactant (up to 5 doses) plus prolonged inhaled nitric oxide (iNO)
Study: 23037875
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) alone
Study: 20335831
Drug: Everolimus 0.75
Normalized name: everolimus 0.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 0.75 mg BID
Study: 20335831
Drug: Everolimus 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 1.5 mg BID
Study: 17621415
Drug: Sulindac (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (200 mg/day, 100 mg twice a day; n = 16 patients)
Study: 9440402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of preliminary notification, short questionnaire, and no mention of telephone contact
Study: 9440402
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of no preliminary notification, long questionnaire, and mention of telephone contact
Study: 10781270
Drug: Hypnotic state
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic state
Study: 26079661
Drug: Enhanced oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced oral healthcare
Study: 26079661
Drug: Usual oral
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual oral healthcare